Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulated Protein Degradation02:58

Regulated Protein Degradation

6.6K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
6.6K
Regulated Protein Degradation02:58

Regulated Protein Degradation

2.5K
2.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A prognostic human brain network for diffuse midline glioma.

Nature·2026
Same author

Treatment and outcomes of immunotherapy related colitis and hepatitis- a multi-centre cohort study in the United Kingdom by the National Oncology Trainee Collaborative for Healthcare Research (NOTCH).

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Monocyte Migration Emerges from a Divergent Chemokine Signaling Network.

bioRxiv : the preprint server for biology·2026
Same author

Development of Potent and Cell Active 5-Azaindole-Based Tau Tubulin Kinase Inhibitors.

bioRxiv : the preprint server for biology·2026
Same author

Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.

Nature medicine·2026
Same author

The Development and Validation of Models of Risk for Behaviours That Challenge in Children With Developmental Disabilities: A Novel Machine Learning Approach.

Journal of intellectual disability research : JIDR·2026
Same journal

Small Molecules in Development for the Treatment of Sepsis: Insights into Drug Targets and Molecular Mechanisms.

Journal of medicinal chemistry·2026
Same journal

Isofagomine Derivatives as TcdB Glucosyltransferase Inhibitors.

Journal of medicinal chemistry·2026
Same journal

The One-Step Incorporation of Boron-10 Atom into Prostate Cancer-Targeted Fluorophores for Visualizing In Vivo Boron-10 Delivery and Intratumoral Distribution with Cellular Resolution.

Journal of medicinal chemistry·2026
Same journal

Design and Evaluation of Conformationally Locked Indole-Carboxylic Acids as Selective THRβ Agonists against MASH.

Journal of medicinal chemistry·2026
Same journal

Drug Screening of Nitroreductase Modulators Using an Atomic-Engineered Activatable Fluorescent Probe for Tumor Imaging.

Journal of medicinal chemistry·2026
Same journal

Reprogramming Acetaminophen Metabolism via Amide-to-Thioamide Modification to Prevent Drug-Induced Liver Injury.

Journal of medicinal chemistry·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.7K

Targeting Activin Receptor-like Kinase 2 Using Heterobifunctional Protein Degraders.

Daniel T Webb1,2, Katherine L Jones2, Natsuko Macabuag2

  • 1Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, United Kingdom.

Journal of Medicinal Chemistry
|May 4, 2026
PubMed
Summary
This summary is machine-generated.

Researchers developed novel ALK2 degraders, M4K3233 and M4K3250, to target bone morphogenetic protein signaling. These compounds show promise for treating fibrodysplasia ossificans progressiva and certain brain cancers.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K
Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry
11:20

Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry

Published on: March 29, 2018

7.1K

Related Experiment Videos

Last Updated: May 5, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.7K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K
Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry
11:20

Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry

Published on: March 29, 2018

7.1K

Area of Science:

  • Medicinal Chemistry
  • Molecular Biology
  • Oncology

Background:

  • Activin receptor-like kinase 2 (ACVR1/ALK2) is crucial for bone morphogenetic protein (BMP) signaling pathways.
  • Dysregulation of ALK2 is implicated in fibrodysplasia ossificans progressiva (FOP), diffuse intrinsic pontine glioma (DIPG), and glioblastoma.

Purpose of the Study:

  • To develop novel chemical degraders targeting ALK2.
  • To investigate the therapeutic potential of ALK2 modulation in human diseases.

Main Methods:

  • Design and synthesis of first-in-class ALK2 degraders.
  • Utilizing M4K3233 as a chemical tool to elucidate ALK2 degradation mechanisms.
  • Optimization of lead compounds to enhance ALK2 degradation potency.

Main Results:

  • Successful development of M4K3233, a potent and selective ALK2 degrader.
  • Identification of M4K3250, a derivative with improved ALK2 degradation efficacy.
  • Demonstration of the utility of these compounds in studying ALK2's role in disease.

Conclusions:

  • The developed ALK2 degraders, including M4K3250, represent a promising new class of therapeutic agents.
  • These compounds offer valuable tools for understanding ALK2-related pathologies.
  • The findings support the translational potential of ALK2 degraders in drug discovery for FOP, DIPG, and glioblastoma.